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Background: In different models of paralytic ileus, cannabinoid receptors are
overexpressed and endogenous cannabinoids are massively released, contributing to
gastrointestinal dysmotility. The antitumoral drug vincristine depresses gastrointestinal
motility and a similar mechanism could participate in this effect. Therefore, our aim was
to determine, using CB1 and CB2 antagonists, whether an increased endocannabinoid
tone is involved in vincristine-induced gastrointestinal ileus.
Methods: First, we confirmed the effects of vincristine on the gut mucosa, by
conventional histological techniques, and characterized its effects on motility, by
radiographic means. Conscious male Wistar rats received an intraperitoneal injection
of vincristine (0.1–0.5mg/kg), and barium sulfate (2.5 ml; 2 g/ml) was intragastrically
administered 0, 24, or 48 h later. Serial X-rays were obtained at different time-points
(0–8 h) after contrast. X-rays were used to build motility curves for each gastrointestinal
region and determine the size of stomach and caecum. Tissue samples were taken for
histology 48 h after saline or vincristine (0.5mg/kg). Second, AM251 (a CB1 receptor
antagonist) and AM630 (a CB2 receptor antagonist) were used to determine if CB1 and/or
CB2 receptors are involved in vincristine-induced gastrointestinal dysmotility.
Key results: Vincristine induced damage to the mucosa of ileum and colon and
reduced gastrointestinal motor function at 0.5mg/kg. The effect on motor function
was particularly evident when the study started 24 h after administration. AM251, but
not AM630, significantly prevented vincristine effect, particularly in the small intestine,
when administered thrice. AM251 alone did not significantly alter gastrointestinal motility.
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Conclusions: The fact that AM251, but not AM630, is capable of reducing the effect of
vincristine suggests that, like in other experimental models of paralytic ileus, an increased
cannabinoid tone develops and is at least partially responsible for the alterations induced
by the antitumoral drug on gastrointestinal motor function. Thus, CB1 antagonists might
be useful to prevent/treat ileus induced by vincristine.
Keywords: chemotherapy-induced adverse effects, cannabinoid, CB1 receptor, gastric emptying, radiology, rat,
vincristine, ileus
INTRODUCTION
Vincristine is a vinca alkaloid widely used in the treatment of
hematological malignancies and solid tumors since the 1960’s
(Johnson et al., 1960; Bohannon et al., 1963). It is a cell
cycle specific agent which blocks mitosis with metaphase arrest
through disruption of the mitotic apparatus and it may affect
several body systems (Rosenthal and Kaufman, 1974). The main
side effect of vincristine is a dose dependent and cumulative
peripheral neuropathy. Paresthesias, loss of tendon reflexes, and
progressive weakness are the most common clinical features,
although autonomic dysfunctions, including gastrointestinal
disturbances, might occur (Rosenthal and Kaufman, 1974; Harris
and Jackson, 1977; Chae et al., 1998; Wang et al., 2000). Indeed,
gastrointestinal complications may be present in up to 30–40%
of patients receiving vincristine and the earliest symptoms may
include colicky abdominal pain, constipation, and adynamic
or paralytic ileus as the major manifestations. Damage to the
myenteric plexus by vinca alkaloids could be implicated in
intestinal hypomotility (Smith, 1967; Kaneko et al., 2001; Peixoto
Júnior et al., 2009). Since constipation is the most widely
recognized manifestation, colonic motility has received the most
attention. But patients treated with vincristine can also develop
symptoms indicating dysmotility of the upper gastrointestinal
tract, including anorexia, and nausea or even extreme symptoms
such as paralytic ileus. In fact, paralytic ileus occurs in 3–12%
of patients, and may be fatal in up to 30% of them (Toghill
and Burke, 1970). However, the impact and mechanisms of
vincristine on gastrointestinal motility have not been deeply
studied in humans or animals.
The endocannabinoid system in the gastrointestinal tract
has attracted much attention because both its activation and
inhibition could be therapeutically useful depending on the
circumstances (Abalo et al., 2012; Abalo and Martín-Fontelles,
2017; Salaga et al., 2017; Vera et al., 2017). Evidence is emerging
that exogenous and endogenous cannabinoids have an important
role in gastrointestinal physiopathology, such as gastrointestinal
inflammation (Izzo and Camilleri, 2009). But cannabinoids
mediate also other functions in the gut, such as gastroprotection
and gastric secretion, gastrointestinal motility, ion transport,
visceral sensation, and cell proliferation (Izzo and Sharkey,
2010). In this sense, plant-derived, endogenous, and synthetic
cannabinoid receptor agonists reduced gastric emptying, upper
gastrointestinal transit and colonic propulsion in rodents (Aviello
et al., 2008; Izzo and Camilleri, 2009; Abalo et al., 2012; Vera et al.,
2017), whereas cannabinoid receptor antagonists may increase
gastrointestinal motility in experimental animals (Izzo et al.,
1999) and cause diarrhea in humans (Waterlow and Chrisp,
2008).
There are functional, biochemical, and immunohistochemical
evidences that alterations in the enteric endocannabinoid system
contribute to causing paralytic ileus in animal models, and
different strategies aimed at normalizing endocannabinoid levels
were useful in these conditions. Actually, the inactivation of
CB1 (Mascolo et al., 2002) or CB1 and CB2 receptors (Li et al.,
2010) were useful in the treatment of paralytic ileus induced
by acetic acid and lipopolysaccharide (LPS), respectively. Thus,
cannabinoid antagonists may be powerful tools in the treatment
of adynamic ileus of different origins.
So far, we have characterized the effect of different drugs in the
gastrointestinal tract of experimental animals using radiographic
methods, including antitumoral drugs, like cisplatin (Cabezos
et al., 2008, 2010; Vera et al., 2014) and 5-fluorouracil (Abalo
et al., 2016; McQuade et al., 2016), and cannabinoids (Abalo et al.,
2009, 2010, 2011, 2015). We have even performed studies of the
combined effects of antitumoral drugs and cannabinoids (Abalo
et al., 2013, 2016). In these regards, we showed that the non-
selective cannabinoid agonist WIN 55, 212-2 was not capable
of improving cisplatin-induced gastrointestinal dysmotility, and
even worsened it (Abalo et al., 2013), whereas at a non-
psychoactive dose, it tended to reduce diarrhea associated to 5-
fluorouracil treatment (Abalo et al., 2016). Thus, these techniques
might be useful to study vincristine effects on gastrointestinal
motor function, and the possible role of cannabinoid agents in
them.
Therefore, the aims of this work were, using radiographic
means: (1) To characterize the effect of the antitumoral drug
vincristine on rat gastrointestinal motor function. (2) To
determine whether the motor alterations induced by vincristine
might be prevented by the CB1-selective cannabinoid antagonist
AM251 and by the CB2-selective cannabinoid antagonist AM630.
Some of the present results were communicated previously in
abstract form (Vera et al., 2012).
MATERIALS AND METHODS
The Ethical Committee at Universidad Rey Juan Carlos
(URJC) and Hospital General Universitario Gregorio Marañón
(HGUGM) approved the study. Experimental procedures were
carried out in accordance with the recommendations of these
Committee as well as with the EU directive for the protection
of animals used for scientific purpose (2010/63/UE) and Spanish
regulations (RD 109 53/2013).
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Animals
Male Wistar rats (350–400 g) were obtained from the Veterinary
Unit of HGUGM (Madrid, Spain) or from Envigo (Barcelona,
Spain) and housed (4/cage), at the Veterinary Units of HGUGM,
or URJC, in standard transparent cages (60× 40× 20 cm), under
environmentally controlled conditions (temperature = 20◦C;
humidity = 60%), with a 12 h light/12 h dark cycle. Animals had
free access to standard laboratory rat chow (Harlan Laboratories
Inc.) and tap water.
Protocol
First, we characterized the effect of a single dose of vincristine
on gastrointestinal architecture and motility by histological and
radiographic means, respectively (see below). Rats received an
acute intraperitoneal injection of vincristine (0.1 or 0.5 mg/kg) or
saline (2–3 ml/kg). Alterations of gastrointestinal motility were
measured immediately, 24 or 48 h after drug administration.
Samples from ileum and colon were taken for conventional
histology 48 h after saline or vincristine (0.5 mg/kg).
A second set of experiments was performed in order to
determine whether the alterations induced by vincristine could
be due to an increased cannabinoid tone and activation of
CB1 or CB2 receptors. In these experiments, vincristine was
administered 24 h prior to the radiographic analysis and adequate
cannabinoid antagonists were tested as follows.
The cannabinoid CB1-selective antagonist AM251 (1 mg/kg),
or its vehicle (1ml/kg), was administered once (20 min
before vincristine), twice (before and 24 h after vincristine),
or thrice (before, 12 and 24 h after vincristine). Thereafter
(24 h after vincristine injection), the radiographic analysis of
gastrointestinal motor function was performed (see below).
In the remaining experiments, the CB2-selective antagonist
AM630 (1mg/kg), or its vehicle (1 ml/kg), was administered
thrice (20 min before, and 12 and 24 h after vincristine) and
gastrointestinal motor function was analyzed as described below.
This group of experiments was performed at URJC, using animals
from Envigo.
Histology
Forty-eight hours after vincristine, samples were obtained from
terminal ileum (at least 10 cm oral to the ileocaecal junction)
and colon of 4–8 animals per experimental group, fixed in
buffered 10% formalin and embedded in paraffin. Sections of
5 µm were stained with hematoxylin-eosin (HE) and studied
under a Zeiss Axioskop 2 microscope equipped with the image
analysis software package AxioVision 4.6. Samples were studied
in duplicate under a 20x objective. Histological damage was
evaluated using a numerical score of 0–3 assigned to each section
considering general loss of mucosal architecture (graded 0–
3, absent to severe) and extent of inflammatory cell infiltrate
(graded 0–3, absent to transmural). The experimenter was blind
to the treatment received by the rat from which the sample under
analysis was obtained.
Gastrointestinal Motility Evaluation
Gastrointestinal motor function was studied by radiographic
methods as previously described (Cabezos et al., 2008).
Thus, 2.5 ml of a suspension of barium sulfate (2 g/ml,
temperature = 22◦C) was administered per os. Experiments at
HGUGMwere performed with a Siemens (Siremobil Compact L,
Erlangen, Germany) digital X-Ray apparatus (60 kV, 7 mA) and
X-rays were captured with NPG Real DVD Studio II software.
For the experiments at URJC, a CS2100 (Carestream Dental,
Spain) digital X-ray apparatus (60 kV, 7 mA) was used, and
X-rays were recorded on Carestream Dental T-MAT G/RA
film (15 × 30 cm) housed in a cassette provided with regular
intensifying screen; films were developed using a Kodak X-omat
2000 automatic processor. Exposure time was adjusted to 20–
60ms. Immobilization of the rats in prone position was achieved
by placing them inside adjustable hand-made transparent plastic
tubes, so that they could not move. Habituation to the
recording chamber prior to commencement of the study did
not significantly alter gastrointestinal motility (Cabezos et al.,
2008). To further reduce stress, rats were released immediately
after each shot (immobilization lasted for 1–2 min). X-rays
were recorded at different times (immediately and 1, 2, 4, 6,
and 8 h) after administration of the contrast medium. While
taking the radiographs, the qualified investigator remained at
least 2m away from the X-ray source or behind a leaded
wall, where radioactivity while shooting was not different from
environmental readings. A trained investigator blind to the
drug administered performed the analysis of the radiographs.
Alterations in gut motility were semiquantitatively determined
from the images by assigning a compounded value to each region
of the gastrointestinal tract considering the following parameters:
percentage of the gastrointestinal region filled with contrast
(0–4); intensity of contrast (0–4); homogeneity of contrast (0–
2); and sharpness of the gastrointestinal region profile (0–2).
Each of these parameters was scored and a sum (0–12 points)
was made. X-rays for characterization of vincristine and AM251
effects were obtained at HGUGM. X-rays to study the effect
of AM630 were taken at URJC. Results were comparable for
controls (triple administration of vehicle) obtained at both
institutions.
The X-ray images were also analyzed with the aid of an image
analysis system (Image J 1.38 for Windows, National Institute
of Health, USA, free software: http://rsb.info.nih.gov/ij/) and the
alterations of stomach size and caecum were studied.
Compounds and Drugs
Barium sulfate (Barigraf R© AD, Juste SAQF, Madrid, Spain) was
suspended in tap water and continuously hand-stirred until
administration.
Vincristine was purchased from Sigma-Aldrich (Spain,
experiments performed at HGUGM) or from Abcam (UK,
experiments performed at URJC) and dissolved in saline.
N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-
4-methyl-1H-pyrazole-3-carboxamide (AM251; Gatley et al.,
1996) and 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-
indol-3-yl](4-methoxyphenyl) methanone (AM630; Hosohata
et al., 1997) were purchased from Ascent Scientific Ltd (North
Somerset, BS24 9 ES, UK).
Cannabinoid antagonists were dissolved in Tocrisolve, a
commercially available water soluble emulsion composed of a
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1:4 ratio of soya oil/water that is emulsified with the block co-
polymer Pluronic F68 (Tocris, Cookson, Bristol, UK; 30 µl in
0.5ml of saline solution).
Statistical Analysis
Data are presented as the mean values ± SEM. Differences
between groups were analyzed using Student’s t-test or two-way
ANOVA followed by post-hoc Bonferroni multiple comparison
test, as appropriate. Values of p < 0.05 were regarded as being
significantly different.
RESULTS
Histopathological Effects of Vincristine on
Intestinal Tissues
The histological pattern of the intestinal wall in HE stained
sections is shown in Figure 1. A general and statistically
significant damage was observed after vincristine administration.
The epithelial layer was particularly affected, showing large
areas with ulcers, and loss of normal architecture both in small
(Figures 1A,B,E, p < 0.01) and large intestine (Figures 1C,D,F,
p < 0.01). On the contrary, there were no differences regarding
the extent of inflammatory nodules between vincristine-treated
animals and controls.
Effects of Vincristine on Gastrointestinal
Motor Function
In control animals, when barium was given immediately after
saline, gastric emptying was complete 4 h after barium. Barium
content reached its maximum in the small intestine in just 1 h and
it completely emptied into the caecum by 4 h. In most animals,
barium started to stain the caecum and the colorectum 2 and
4 h after barium, respectively. Both organs filled progressively
until the end of the study (Figure 2). When barium was given
24 (Figure 3) or 48 h (Figure 4) after saline, the motility curves
were very similar to those obtained immediately after saline
administration.
Compared with saline, acute administration of vincristine
immediately before barium administration (0 h), did not induce
any significant change on gastrointestinal motility, irrespective of
the dose studied. Also, the quantitative analysis of the images did
not show any significant change in the stomach or caecum size
(Figure 2).
Remarkably, vincristine intensely and significantly reduced
gastrointestinal motor function when this was radiographically
evaluated 24 h after administration, but only at the dose of
0.5mg/kg. In these animals, gastric emptying was progressive
but at a much lower rate than in rats treated with saline or
vincristine at 0.1mg/kg (Figure 3A). Intestinal transit and filling
of caecumwere also delayed in vincristine-treated rats at the high
dose (Figures 3B,C). Furthermore, at the end of the experiment
(8 h), contrast had not reached the colorectal region in any of
those animals (Figure 3D). These results were confirmed in the
quantitative analysis of the images. In rats treated with vincristine
at 0.5mg/kg, the stomach size at the beginning of the experiment
was increased compared to saline-treated animals and remained
unchanged for the rest of the experiment (Figure 3E). In
the caecum, vincristine had a dual effect; the lower dose of
vincristine increased its size and the higher one reduced it
(Figure 3F).
When serial X-rays were obtained 48 h after vincristine,
gastrointestinal motor function was still decreased, although
the effect was less pronounced than in the previous experiment.
Gastric emptying and intestinal transit were reduced
(Figures 4A,B), but gastric emptying started to recover 6 h
after barium (54 h after vincristine), at least in some animals,
and higher levels of barium contents were reached in the
small intestine at all time-points. The effect on caecum was
similar to the previous experiment, but that on the colorectum
was less intense and fecal pellets were seen in some animals
(Figures 4C,D). These results were confirmed in the quantitative
analysis. Thus, 0 h after contrast (48 h after vincristine), the
stomach size was again comparable to that in the saline group,
but not much further change was apparent in this region
(Figure 4E). Vincristine reduced the size of the caecum at the
highest dose used (Figure 4F).
Effect of the Cannabinoid Antagonists on
Ileus Induced by Vincristine
Figure 5 shows the motility curves for controls used in this
experiment. In addition to the effect of saline, the effect of
injecting the cannabinoid vehicle once (20 min before saline),
twice (before and 24 h after saline) and thrice (before, 12
and 24 h after saline) is shown. As can be seen, injecting
the vehicle only once did not produce any effect compared
to saline-treated animals. However, when it was injected twice
or thrice, significant delays in gastric emptying and in filling
of small intestine and caecum were seen. For the following
experiments, the effects of the different drugs are compared
to those of the vehicle given thrice, since it was the pattern
which induced more changes compared to saline (although still
very different to that found in vincristine-treated animals, see
below).
Figure 6 shows that the CB1 antagonist AM251 (1 mg/kg)
improved gastrointestinal motor function compared to
vincristine-treated rats and that this effect increased with
the number of times it was injected (3 > 2 > 1). However,
the normalizing effect of AM251 was different in each
gastrointestinal region. Thus, in the stomach and colorectum,
AM251 given thrice exerted a significant but relatively small
effect. In contrast, it almost normalized the motility curve in
the small intestine, and completely normalized the curve in the
caecum. Efficacy of AM251 was lower in animals treated with the
compound only twice and even lower when it was administered
only once. AM251 given thrice did not exert any significant effect
compared to its vehicle given also thrice.
Finally, the effect of the selective CB2 antagonist AM630 was
tested. For ethical reasons, and due to the fact that the CB1
antagonist showed the best results after its triple administration,
we only used this pattern of administration to test the effect of
AM630. In high contrast with the effect of AM251, the triple
administration of AM630 did not significantly modify the effect
of vincristine (Figure 7).
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FIGURE 1 | Effect of vincristine treatment on the general structure of the rat intestine. Rats were injected intraperitoneally with vincristine (0.5mg/kg) or saline
(1–2ml/kg). Forty-eight hours after treatment, histological samples were embedded in paraffin, and stained with HE. Left row, small intestine: tissue samples from
saline (A) and vincristine-treated animals (C) showing the damaged mucosa; quantitative analysis of the histological damage (E). Right row, colorectum: tissue
samples from saline (B) and vincristine-treated animals (D) showing the damaged mucosa; quantitative analysis of the histological damage (F). Bars show mean
values ± SEM for control (white) and vincristine-treated animals (red). Each group consisted of 4–8 rats. **p < 0.01 vs. saline; (Student’s t-test). Scale bar: 100µm.
DISCUSSION
This is the first work in which vincristine-induced
gastrointestinal dysmotility has been characterized using
radiographic methods in experimental animals. In
addition, we have demonstrated that the selective CB1
cannabinoid antagonist AM251 (but not AM630, a CB2
selective antagonist), is capable of reducing the effect
of vincristine, suggesting that an increased cannabinoid
tone is, atleast partially, responsible for the alterations
induced by this antitumoral drug on gastrointestinal motor
function.
Vincristine Effect on Gastrointestinal Motor
Function in the Rat
Gastrointestinal dysmotility associated to vinca alkaloids,
including vincristine, is a known cause of drug-induced
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FIGURE 2 | Effect of vincristine immediately after administration on gastrointestinal motor function in the rat. Gastrointestinal motor function was
evaluated by radiological methods (see text) in: (A) stomach (gastric emptying); (B) small intestine; (C) caecum and (D) colorectum. Rats were injected
intraperitoneally (i.p.) with: saline (1–2 ml/kg) or vincristine at 0.1 (VC 0.1) or 0.5 mg/kg (VC 0.5). Barium sulfate (2.5ml, 2 g/ml) was intragastrically administered
immediately after drug administration and X-rays were taken 0–8 h after. The size of stomach (E) and caecum (F) was determined with Image J. Data represent
mean ± SEM (two-way ANOVA followed by post-hoc Bonferroni multiple comparison test). (G,H) Representative images of animals treated with saline and VC 0.5,
taken at different times throughout the experiment. n = 8 each group. Scale bar: 23mm.
gastrointestinal toxicity (Bradley, 1968). Here, vincristine
did not significantly alter gastrointestinal motility at a low
(0.1mg/kg) or high dose (0.5mg/kg) when the X-ray study
was performed immediately after its administration. However,
when the radiographic study was carried out 24 or 48 h after
the antitumoral drug at 0.5mg/kg, an intense and significant
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FIGURE 3 | Effect of vincristine 24 h after administration on gastrointestinal motor function in the rat. Gastrointestinal motor function was evaluated by
radiological methods (see text) in: (A) stomach (gastric emptying); (B) small intestine; (C) caecum and (D) colorectum. Rats were injected intraperitoneally (i.p.) with:
saline (1–2 ml/kg) or vincristine at 0.1 (VC 0.1) or 0.5 mg/kg (VC 0.5). Barium sulfate (2.5 ml, 2 g/ml) was intragastrically administered 24 h after drug administration
and X-rays were taken 0–8 h after. The size of stomach (E) and caecum (F) was determined with Image J. Data represent mean ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001 vs. saline (two-way ANOVA followed by post-hoc Bonferroni multiple comparison test). (G,H) Representative images of animals treated with saline and
VC 0.5, taken at different times throughout the experiment. n = 8 each group. Scale bar: 23 mm.
decrease in gastric emptying and intestinal transit was observed.
These results indicate that vincristine-induced dysmotility
may need a relatively long time to occur or that higher
doses might be needed to see early effects of this drug on
gastrointestinal motor function. We did not increase the dose
or the observation time because the higher dose used here
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FIGURE 4 | Effect of vincristine 48 h after administration on gastrointestinal motor function in the rat. Gastrointestinal motor function was evaluated by
radiological methods (see text) in: (A) stomach (gastric emptying); (B) small intestine; (C) caecum and (D) colorectum. Rats were injected intraperitoneally (i.p.) with:
saline (1–2 ml/kg) or vincristine at 0.1 (VC 0.1) or 0.5 mg/kg (VC 0.5). Barium sulfate (2.5 ml, 2 g/ml) was intragastrically administered 48 h after drug administration
and X-rays were taken 0–8 h after. The size of stomach (E) and caecum (F) was determined with Image J. Data represent mean ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001 vs. saline (two-way ANOVA followed by post-hoc Bonferroni multiple comparison test). (G,H) Representative images of animals treated with saline and
VC 0.5, taken at different times throughout the experiment. n = 8 each group. Scale bar: 23mm.
was similar to the LD50 in rats and mortality associated to this
dose may occur 4–6 days after its administration (Uy et al.,
1967).
Several previous investigations have reported that vincristine-
induced gastric hypomotility is not an early event (Kaneko et al.,
2001; Tsukamoto et al., 2011). The delayed effect of vincristine
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FIGURE 5 | Effect of saline or the cannabinoid vehicle on gastrointestinal motor function in the rat. Gastrointestinal motor function was evaluated by
radiological methods (see text) in: (A) stomach (gastric emptying); (B) small intestine; (C) caecum and (D) colorectum. Rats were injected intraperitoneally (i.p.) with:
saline (1–2ml/kg) or the cannabinoid vehicle once (20 min before saline, Veh-1), twice (before and 24 h after saline, Veh-2), and thrice (before, 12 and 24 h after saline,
Veh-3). Barium sulfate (2.5 ml, 2 g/ml) was intragastrically administered immediately or 24 h after drug administration and X-rays were taken 0–8 h after. Data
represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. saline (two-way ANOVA followed by post-hoc Bonferroni multiple comparison test). n = 4–8 animals
per group. (E) Representative images of saline- and Veh-treated animals 2 h after contrast. Scale bar: 23 mm.
contrasts with that of other antineoplastic drugs, like cisplatin,
which provokes gastric dysmotility within a much shorter time
in rats (Cabezos et al., 2008, 2010; Vera et al., 2014). Cisplatin
immediate (acute) effect on gastric motor function is due to
serotonin release and vagal activation, through the stimulation
of 5-HT3 receptors (Vera et al., 2014), and underlies its intense
emetogenic effect in experimental animals (Holmes et al., 2009;
du Sert et al., 2011; Horn, 2014) and humans (Navari, 2013).
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FIGURE 6 | Effect of the CB1 antagonist AM251 on the alterations induced by vincristine on gastrointestinal motor function in the rat. Gastrointestinal
motor function was evaluated by radiological methods (see text) in (A) stomach (gastric emptying); (B) small intestine; (C) caecum and (D) colorectum. Rats received
two intraperitoneal injections (i.p.). One was saline (1–2 ml/kg) or vincristine at 0.5 mg/kg (VC). The other one was the cannabinoid vehicle given three times (Veh-3) or
AM251 given once (20 min before saline or vincristine: AM251-1), twice (before and 24 h after saline or vincristine: AM251-2), or thrice (before, 12 and 24 h after saline
or vincristine: AM251-3). Barium sulfate (2.5 ml, 2 g/ml) was intragastrically administered 24 h after saline or vincristine administration and X-rays were taken 0–8 h
after. Data represent mean ± SEM. *p < 0.05, ** p < 0.01, ***p < 0.001 vs. Veh-3; ## p < 0.01; ###p < 0.001 vs. Veh 3 + VC (two-way ANOVA followed by post-hoc
Bonferroni multiple comparison test). n = 4–8 animals each group. (E) Representative images of the different treatments 8 h after contrast. Scale bar: 23 mm.
Cisplatin may also produce “delayed” emesis in humans, and
we observed “delayed” gastric dysmotility and pica, a surrogate
marker of nausea in rodents (Takeda et al., 1993), after cisplatin
administration in the rat (Cabezos et al., 2008). Cisplatin-
induced delayed emesis seems to be more dependent upon
other mechanisms, including the activation of NK1 receptors
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FIGURE 7 | Effect of the CB2 antagonist AM630 on the alterations induced by vincristine on gastrointestinal motor function in the rat. Gastrointestinal
motor function was evaluated by radiological methods (see text) in: (A) stomach (gastric emptying); (B) small intestine; (C) caecum and (D) colorectum. Rats received
saline (1–2 ml/kg) or vincristine at 0.5 mg/kg (VC). The cannabinoid vehicle (Veh-3) or AM630 (AM630-3) were administered thrice (before, 12 and 24 h after saline or
vincristine administration). Barium sulfate (2.5 ml, 2 g/ml) was intragastrically administered 24 h after saline or vincristine administration and X-rays were taken 0–8 h
after. Data represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. Veh-3 (two-way ANOVA followed by post-hoc Bonferroni multiple comparison test). n = 8
each group. (E) Representative images of the different treatments 8 h after contrast. Scale bar: 30mm.
through the release of substance P (Navari, 2013; Rudd et al.,
2016). These mechanisms justify the usefulness of 5-HT3 and
NK1 antagonists for prevention of emesis associated to highly
emetogenic chemotherapy in cancer patients (Navari, 2013).
Vincristine may induce nausea and emesis in dogs and humans,
but the incidence and intensity of these effects are much lower
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than with cisplatin (Navari, 2013; Mason et al., 2014) and the
mechanisms might be different (see below).
The altered motility curve observed here for the small
intestine 24 h after vincristine may be due, at least partly, to
the delayed gastric emptying (barium reached the small intestine
much later in vincristine- than in saline-treated animals).
However, this would probably have produced a motility curve for
the small intestine very similar in shape to that in control animals,
but displaced to the right (this occurred after acute cisplatin,
which only alters gastric motility; Cabezos et al., 2008). In the
present study, the curve was completely distorted, suggesting
that vincristine produced direct effects in this region. Direct
effects of vincristine in the small intestine might include altered
myoelectric activity, increased tone and spasmogenic actions,
as previously suggested (Sharma, 1979, 1988; Sninsky, 1987).
Small intestinal transit was accelerated in rats in the first few
hours after vinblastine (Sharma, 1979), but we did not detect
such an effect of vincristine in our non-invasive study. In fact,
the motility curve of caecum looked very similar (parallel) to
that in control animals both 24 and 48 h after vincristine (0.5
mg/kg), but displaced to the right, further suggesting that small
intestinal transit was delayed. Interestingly, in spite of the fact
that caecum filled adequately, there was a complete absence
of stained fecal pellets in vincristine-treated rats for the whole
duration of the radiologic study when it was performed 24 h
after the antitumoral drug, suggesting that vincristine directly
suppressed motility in colorectum, which is in accordance with
the reports of constipation associated to treatment with vinca
alkaloids, in both animals and humans (Harris and Jackson, 1977;
Garewal and Dalton, 1985; Ikehara, 1992; Leker et al., 1997; Chae
et al., 1998; Wang et al., 2000; Essa et al., 2014; Yasu et al.,
2016).
Several factors may contribute to the effects found in the
stomach, small intestine, caecum and colorectum 24–48 h after
vincristine. Chemotherapy-induced gastrointestinal toxicity can
be caused by direct damage to mucosal epithelial cells or by
stimulation of the vomiting center or chemoreceptor trigger
zone (Kaneko et al., 2001). Vincristine is known to induce
metaphase arrest, severe villous atrophy and mucosal erosions
(Beró and Jávor, 1985), which we found in our histological study.
This effect would disrupt the intestinal barrier function and
could contribute to dysmotility. In contrast, we did not observe
evident changes in the presence of inflammatory cells within
the gut wall, suggesting that these might not be determinant
to acute vincristine-induced dysmotility, although this must be
systematically studied. According to previous reports, direct
effects on the smooth muscle layers (Kaneko et al., 2001) or
the possible influence of enhanced adrenergic activity due to
neuropathic pain (Peixoto Júnior et al., 2009) seem unlikely.
Interestingly, due to the known neurotoxicity of the compound
(whose direct effect on the vomiting center to induce gastric
dysmotility and emesis cannot be discarded) and to several
functional and histological evidences, the development of an
autonomic neuropathy has been suggested to contribute to
vincristine-induced gastrointestinal hypomotility, particularly
after high doses or chronic treatments (Smith, 1967; Peixoto
Júnior et al., 2009). However, a systematic analysis of the possible
changes in structure and in marker expression in the enteric
nervous system after vincristine treatment, as those performed
with other antineoplastic drugs (Vera et al., 2011; Wafai et al.,
2013; McQuade et al., 2016), is still required to define the
precise role of neuropathy affecting the enteric nervous system,
particularly the myenteric plexus, on gastrointestinal motor
disturbances induced by vincristine. This might be particularly
evident in chronic treatments.
Importantly, gastrointestinal ileus induced by vincristine, in
contrast to sensory neuropathy, seems to be transient and is
reverted soon after treatment discontinuation (Sharma, 1988;
Chae et al., 1998; Peixoto Júnior et al., 2009). However,
in addition to reducing quality of life, vincristine-induced
gastrointestinal dysmotility may be problematic and even
fatal, particularly under certain circumstances (liver failure,
concomitant condition predisposing to constipation, drug
interactions, or even accidental overdose: (Toghill and Burke,
1970; Leker et al., 1997; Bermúdez et al., 2005; Uner et al., 2005;
Levêque et al., 2009; Diezi et al., 2010; Le Guellec et al., 2012; Essa
et al., 2014; Yasu et al., 2016). This justifies the search for anti-ileus
treatments.
Very few agents have been tested in vincristine-induced
gastrointestinal ileus and most references are case reports with
low numbers of subjects (Harris and Jackson, 1977; Jackson et al.,
1982; Garewal and Dalton, 1985; Ikehara, 1992; Tsukamoto et al.,
2011; Essa et al., 2014; Mason et al., 2014). To the best of our
knowledge, the possible role of cannabinoids has never before
been tested either in experimental animals or in the clinic.
Role of Cannabinoids on Gastrointestinal
Ileus Induced by Vincristine
Cannabinoids have been used empirically and traditionally to
treat different disorders including those of the gut, ranging
from enteric infections and inflammatory conditions to motility
alterations, emesis, and abdominal pain (Izzo and Camilleri,
2009; Izzo and Sharkey, 2010; Abalo et al., 2012; Abalo
and Martín-Fontelles, 2017; Salaga et al., 2017; Vera et al.,
2017). Central and peripheral cannabinoid receptors seem
to be involved in the regulation of gastrointestinal motility.
Cannabinoid CB1 receptors are mainly found in nervous cells,
including those of the myenteric plexus (Abalo et al., 2012;
Vera et al., 2017), principal responsible for intestinal motility.
Interestingly, these gastrointestinal CB1 receptors appear to exert
a tonic control over the enteric nervous system, and operate as
a “brake” for neural over-reactivity (Schicho and Storr, 2011;
Abalo et al., 2012). In fact, agonists acting at CB1 receptors
may potently depress gastrointestinal motor function even in
the absence of significant central effects (Abalo et al., 2015). In
contrast, CB2 receptors are mainly found in immune cells, and
have anti-inflammatory effects (Turcotte et al., 2016). Normally,
CB2 agents do not alter gastrointestinal motor function (Abalo
et al., 2009, 2010, 2011, 2015). However, it has been shown that
CB2 receptors are overexpressed in the myenteric neurons under
inflammatory conditions, and in such cases, they may also reduce
transit and normalize intestinal motor function (Mathison et al.,
2004; Duncan et al., 2008; Wright et al., 2008). Thus, selective
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CB1 and CB2 cannabinoid receptor antagonists may be useful in
situations in which gastrointestinal motor function is reduced.
The effect of CB1 antagonists on motility in control
animals is to some extent controversial, with some reports
showing increased transit (Mathison et al., 2004) and others
showing no effects (Landi et al., 2002), suggesting that the
gastrointestinal cannabinoid tone may be sensitive to slight
differences in experimental conditions (Abalo et al., 2009,
2010, 2011, 2015). In humans, diarrhea was present in some
obese patients treated with rimonabant and other cannabinoid
antagonists (Waterlow and Chrisp, 2008). In animal models of
paralytic ileus, CB1 receptor was overexpressed and anandamide
levels were increased (Mascolo et al., 2002; de Filippis et al.,
2008). Thus, an increased cannabinoid tone, due to released
endocannabinoids and/or CB1 overexpression, seem to be
involved in the development of paralytic ileus and strategies
aimed at normalizing endocannabinoid levels/tone could be
therapeutically useful in these conditions. Consequently, the CB1
selective antagonist AM251 (with IC50 = 8 nM, K i = 7.49 nM,
and 306-fold selectivity over CB2 receptors, Lan et al., 1999) was
used here to see if vincristine effects are mediated by a similar
mechanism.
In our study, AM251, at a dose that lacked any significant
effect on GI motility in control animals (1 m/kg), reduced the
effect of vincristine on gastric emptying and intestinal transit.
This was achieved when the antagonist was administered twice
(once every 24 h) or thrice (once every 12 h). The gastrointestinal
region most sensitive to the effect of the CB1 antagonist was
the small intestine, and transit was close to normal after its
triple administration, as suggested by the motility curves for
the small intestine and, even more, for the caecum, which
showed normal filling. In contrast, altered gastric emptying
and colorectal motility after AM251 triple administration only
partially improved at the end of the study (8 h after contrast,
32 h after vincristine). Thus, an increase in cannabinoid tone
affecting CB1 receptors might underlie some of the effects of
vincristine in the stomach and colorectum, but other factors may
be more influential in these regions, whereas vincristine-induced
small intestinal ileus seems to depend mostly, if not completely,
on increased CB1 receptor activity. Accordingly, in LPS-induced
septic models of ileus, AM251 increased myoelectric activity of
rat jejunum in vitro and upper gastrointestinal transit in mice
(measured with the charcoal method; Li et al., 2010). Rimonabant
(another CB1 antagonist receptor) alleviated gastrointestinal
symptoms in a murine model of paralytic ileus induced by
intraperitoneal injection of acetic acid, modeling peritonitis,
and an anandamide uptake inhibitor worsened motility even
further (Mascolo et al., 2002). On the other hand, in a model of
postoperative ileus, upper gastrointestinal transit was similarly
reduced in wild type and knock-out mice for CB1 receptors
(although the inflammatory response was more intense in the
latter), suggesting that altered motility in this model might not
be necessarily or only due to increased CB1 receptor activation
(Li et al., 2013a).
Since AM251 (and rimonabant) is considered both an
antagonist and an inverse agonist, at this stage it is not
clear if our results are due to an increased basal activity
of CB1 receptors after vincristine, linked to overexpression,
and/or to the release of endocannabinoids. As mentioned
above, increased anandamide levels were found to occur in
models of paralytic ileus (Mascolo et al., 2002), and expression
of CB1 receptors was increased in different models of ileus
(Mascolo et al., 2002; de Filippis et al., 2008). Interestingly, the
motility curves obtained from vincristine-treated animals here
were very similar to those previously obtained from control
animals treated with cannabinoids, whose effects were dependent
upon CB1 activation and much more potent on intestinal
regions (particularly the small intestine) than on the stomach
(Abalo et al., 2009, 2010, 2015), suggesting that the release
of endogenous cannabinoids might be involved in vincristine
effects.
AM630 did not significantly modify the effect of vincristine on
gut motility. The involvement of CB2 receptors in experimental
models of ileus is less clear than that of CB1 receptors.
Thus, in models of septic ileus, some researchers described
that inactivation of either CB1 or CB2 receptors normalized
jejunal myoelectric activity and upper gastrointestinal transit (Li
et al., 2010). In contrast, inactivation of CB2 receptors did not
normalize reduced motility associated to intraperitoneal acetic
acid administration (Mascolo et al., 2002).
Finally, it cannot be discarded that AM251 exerted its
effects through another mechanism. Interestingly, it has been
described as a GPR55 agonist (EC50 = 39 nM; Henstridge
et al., 2010). As mentioned above, when used alone in control
animals, gastrointestinal motility was not significantly altered,
suggesting that GPR55 receptors were not activated in these
animals. O-1602, another agonist of GPR55 receptors (but 3-
fold more potent than AM251 upon them: EC50 = 13 nM),
did not alter upper gastrointestinal transit when used at 10
mg/kg in control or LPS-treated mice (which showed reduced
transit), whereas cannabidiol, which is considered a GPR55
antagonist, counteracted O-1602, and LPS-effect (Lin et al., 2011;
Li et al., 2013b). Thus, if GPR55 was overexpressed by vincristine
treatment, as by LPS, it is more likely that a GPR55 antagonist was
more useful to counteract GPR55 overactivation than a GPR55
agonist like AM251. The involvement of GPR55 receptors in
vincristine-induced dysmotility will be specifically investigated in
future work.
In conclusion, the fact that AM251 (but not AM630) is
capable of reducing the effect of vincristine suggests that, like
in other experimental models of paralytic ileus, an increased
cannabinoid tone acting through CB1 receptors is, at least
partially, responsible for the alterations induced by vincristine
on gastrointestinal motor function. The combination of different
technniques, including immunohistochemistry (to locate the
cells expressing the receptors) and molecular biology (to
determine the levels of receptors and ligands, if appropriate),
will help determine the precise mechanism of action involved in
AM251 effect. Whatever this may be, ours is a clinically relevant
finding and encourages the exploration of strategies aimed at
reducing CB1 receptor activity to prevent or palliate vincristine-
induced ileus in the clinic.
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